An example is CBFA2T3-GLIS2 AML, where luveltamab tazevibulin, an antibody-drug conjugate (ADC), is currently being employed as a bridge to transplant and/or maintenance therapy (MT) post-transplantation (Supplementary Table 1). This evidence concerns the gene GLIS2 and acute myeloid leukemia.